I don’t think the regulatory barrier against mRNA vaccines were completely unreasonable. If we for example at a recent paper that describes the problems with PEGylated anything (including mRNA) from 2019:
The administration of PEGylated drugs can lead to the production of anti-PEG antibodies(anti-PEG immunoglobulin M (IgM)) and immune response (Figure 1) [30]. Due to these phenomena,the PEG-conjugation of drugs/NPs often only provides a biological advantage during the first dose of a treatment course. By the second dose, the PEGylated agents have been recognized by themononuclear phagocyte system in the spleen and liver and are rapidly cleared from circulation.
We now have a way to deliever mRNA a few times per person to people but outside of pandemic conditions it’s unclear why you want to make the few times that you can effectively give mRNA to a person a vaccine that likely could be made is well via established methods at the cost of maybe not being able to give the person later an mRNA cancer treatment because of too much PEG immunogenicity.
The side effects of the second dose of an mRNA vaccines we see currently are higher then the side effects we see from our well tested vaccine formulations.
I don’t think the regulatory barrier against mRNA vaccines were completely unreasonable. If we for example at a recent paper that describes the problems with PEGylated anything (including mRNA) from 2019:
We now have a way to deliever mRNA a few times per person to people but outside of pandemic conditions it’s unclear why you want to make the few times that you can effectively give mRNA to a person a vaccine that likely could be made is well via established methods at the cost of maybe not being able to give the person later an mRNA cancer treatment because of too much PEG immunogenicity.
The side effects of the second dose of an mRNA vaccines we see currently are higher then the side effects we see from our well tested vaccine formulations.